Population-based estimate of the prevalence of HER-2 positive breast cancer tumors for early stage patients in the US.
The goal of this study was to estimate prevalence of HER-2 positive tumors in a population-based sample of 1026 women diagnosed in 2005 with early stage breast cancer. We modeled the relationship between patient and tumor characteristics and HER-2. HER-2 positive estimates were 19% for women aged ≤ 49 years and 15% aged ≥ 50 years. HER-2 varied by tumor grade and size in women aged ≤ 49 years but was not significant in multivariate analysis. Tumor grade and race were associated with HER-2 for women aged ≥ 50 years after controlling for other variables. HER-2 varies by age and by race and tumor in older women.
Cronin
Kathleen A
KA
Surveillance Research Program, National Cancer Institute, Bethesda, Maryland, USA. cronink@mail.nih.gov
Harlan
Linda C
LC
Dodd
Kevin W
KW
Abrams
Jeffrey S
JS
Ballard-Barbash
Rachel
R
D001741:Black or African American / Q000706:statistics & numerical data; D001213:Asian / Q000706:statistics & numerical data; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000208:ethnology / Q000378:metabolism / Q000473:pathology; D005260:Female; D006630:Hispanic or Latino / Q000706:statistics & numerical data; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D011159:Population Surveillance / Q000379:methods*; D015995:Prevalence; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D018426:SEER Program / Q000706:statistics & numerical data*; D014481:United States / Q000453:epidemiology; D044465:White People / Q000706:statistics & numerical data
D018719:Erb-b2 Receptor Tyrosine Kinases